

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Withdrawn) A method for identifying genes which are up- or down-regulated in intestinal tissue of patients who have, or are at risk of developing, an inflammatory bowel disease or disorder, comprising:
  - (i) generating a first library of nucleic acid probes representative of genes expressed by intestinal tissue of an animal without apparent symptoms and/or risk for an inflammatory bowel disease or disorder;
  - (ii) generating a second library of nucleic acid probes representative of genes expressed by intestinal tissue of an animal which has symptoms of, and/or is at risk for developing, an inflammatory bowel disease or disorder; and
  - (iii) identifying genes that up- or down-regulated, e.g., by at least a predetermined fold difference, in the second library of nucleic acids relative to the first library of nucleic acids.
2. (Withdrawn) The method of claim 1, including the further step of cloning those genes which are up- or down-regulated.
3. (Withdrawn) The method of claim 1, including the further step of generating nucleic acid probes for detecting the level of expression of those genes which are up- or down-regulated.
4. (Withdrawn) The method of claim 1, including the further step of providing kits, such as microarrays, including probes for detecting the level of expression of those genes which are up- or down-regulated.
5. (Withdrawn) A method for determining the phenotype of a cell, particularly a cell of intestinal origin, comprising detecting the differential expression, relative to

a normal cell, of at least one gene shown in Table 1 (herein the "IBD gene set"), or other IBD genes identified according to the method of claim 1.

6. (Withdrawn) The method of claim 5, wherein the assay detects a difference in the level of expression of an IBD gene of at least a factor of two.

7. (Withdrawn) The method of claim 5, which is used to assess a patient's risk of having, or developing, an inflammatory bowel disease.

8. (Withdrawn) A kit for assessing a patient's risk of having or developing an inflammatory bowel disease, comprising

(i) detection means for detecting the differential expression, relative to a normal cell, of at least five genes shown in Table 1 (herein the "IBD gene set") or the gene products thereof; and

(ii) instructions for correlating the differential expression of IBD genes or gene products, if any, with a patient's risk of having or developing an inflammatory bowel disease.

9. (Withdrawn) The kit of claim 8, wherein the detection means includes nucleic acid probes for detecting the level of mRNA of the IBD genes.

10. (Withdrawn) The kit of claim 8, wherein the detection means includes nucleic acid probes for detecting the presence of mutations or changes in methylation patterns to genomic sequences encoding the IBD genes.

11. (Withdrawn) The kit of claim 8, wherein the detection means includes an immunoassay for detecting the level of IBD gene products.

12. (Withdrawn) A method of doing a business for assessing a patient's risk of having or developing an inflammatory bowel disease, comprising

(i) providing a service for determining the level of expression of an IBD gene set or gene products thereof, and comparing the level of expression to a normal cell; and

(ii) assessing a patient's risk of having or developing an inflammatory bowel disease, if any, by determining the correlation between the differential expression of IBD genes or gene products with known changes in expression of IBD genes measured in other patients' suffering from an inflammatory bowel disease.

13. (Withdrawn) A method for treating a patient who has developed, or is at risk of developing, an inflammatory bowel disease comprising:

(i) detecting the differential expression, relative to a normal cell, of at least one IBD gene;

(ii) proscribing a course of treatment dependent on the level of expression of the IBD gene(s) relative to normal cells.

14. (Canceled)

15. (Canceled)

16. (Withdrawn) A drug screening assay comprising

(i) administering a test compound to an animal having an inflammatory bowel disease, or a cell composition isolated therefrom;

(ii) comparing the level of IBD gene expression in the presence of the test compound with one or both of the level of IBD gene expression in the absence of the test compound or in normal cells; wherein test compounds which cause the level of expression of one or more IBD genes to approach normal are candidates for drugs to treat inflammatory bowel diseases.

17. (Withdrawn) A method for treating an animal having an inflammatory bowel disease comprising administering a compound identified by the assay of claim 16.

18. (Withdrawn) A pharmaceutical preparation for treating an animal having an inflammatory bowel disease comprising a compound identified by the assay of claim 16 and a pharmaceutically acceptable excipient.

19-26. (Canceled)

27. (Currently amended) An array for diagnosing inflammatory bowel disease (IBD) in a subject comprising:

(a) nucleic acid probes for determining an expression level of at least ~~one~~ three ~~gene-product~~ genes in a sample from said subject, wherein said ~~gene-product is an mRNA of a~~ gene genes are selected from the group consisting of macrophage inflammatory protein-2 $\beta$  (GRO3), neutrophil lipocalin (HNL), elastase specific inhibitor (elafin), and type VI collagen  $\alpha 3$  chain (COL6A3); and

(b) a substrate to which said nucleic acid probes are bound, wherein a difference in the expression level of each of said ~~gene-product~~ genes in said subject compared to an expression level of ~~said gene-product~~ the same gene in [[a]] healthy subject tissue indicates that said subject has IBD or is at risk of developing IBD.

28. (Previously presented) The array of claim 27, wherein said IBD is ulcerative colitis (UC).

29. (Canceled)

30. (Canceled)

31. (Currently amended) The array of claim 27, wherein the expression level of each of said ~~gene-product~~ genes differs from the expression level of the same gene in healthy tissue by at least a factor of two.

32. (Previously presented) The array of claim 27, wherein said sample is a needle biopsy core, a surgical resection sample, a bowel sample, lymph node tissue, or serum.

33. (Previously presented) The array of claim 27, wherein said nucleic acid probes specifically hybridize to said gene product.

34. (Previously presented) The array of claim 27, wherein said nucleic acid probes are bound to said substrate by covalent bonds or hydrophobic interactions.

35. (Previously presented) The array of claim 27, wherein said nucleic acid probes are spotted onto said substrate in a two-dimensional matrix or array.

36. (Previously presented) The array of claim 27, wherein said substrate is selected from the group consisting of paper, membranes, filters, chips, pins, and glass.